Application of ursolic acid in the preparation of drugs for improving spermatogenesis disorders
Through the preparation and administration of ursoketoic acid, the problem of lack of effective treatment of oligospermia in the prior art has been solved, the sperm count and testicular tissue recovery have been significantly improved, and the effect of improving sperm disorders and promoting fertility has been achieved. Low toxicity and minor side effects.
Patent Information
- Application Number
- CN202311661276.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-06
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2043-12-06
AI Technical Summary
The lack of effective drugs in the prior art for the treatment of oligospermia in male infertility diseases. The target and mechanism of ursoketone acid have not been fully explored, and it is difficult to purify in the laboratory, resulting in pharmacological research. limited.
Ursoke acid was prepared by dissolving ursolic acid in dichloromethane and reacting with pyridine dichlorochromate salt, eluting by thin layer chromatography and column chromatography, and administering it through intraperitoneal injection or oral administration to improve biogenesis Sperm disorders, increase sperm concentration and promote fertility.
Ursoketone significantly improves sperm count and mobility in oligospermia mice, improves testicular tissue morphology, has low toxicity and minor side effects, and is suitable for improving spermatogenesis disorders and promoting fertility.
Smart Images

Figure CN117530950B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical technology, and specifically relates to a preparation method of ursolic acid, a derivative of a triterpenoid compound ursolic acid, and application of ursolic acid in improving oligospermia in treating male infertility diseases. Background Art
[0002] Ursonic acid is a pentacyclic triterpenoid compound that is found in different parts of various plants used in traditional herbal medicine, such as the fruits of hawthorn, apple and jujube, the resins of Pistacia chinensis, Mexican agarwood, the roots of Dipterocarpaceae, Toona sinensis, Areca catechu and Banyan tree, the leaves of Verbenaceae and Rauwolfia emetica.
[0003] Since the synthesis pathway of ursolic acid in plants is very complex, its content is extremely low and it is very difficult to purify in the laboratory, there is no extensive pharmacological research on ursolic acid. However, triterpenoids have shown anti-cancer, anti-inflammatory and antioxidant effects in both in vitro and in vivo studies by regulating transcription factors such as NF-κB and STAT3. Other triterpenoid compounds such as ursolic acid have been extensively studied in pharmacology and are a hot spot for the research and development of various antioxidant products. The widespread presence of ursolic acid in herbal medicines indicates that it can play a therapeutic potential for diseases such as cancer and infectious protozoa. The research and development prospects of the antioxidant and antibacterial effects of ursolic acid on animals are broad.
[0004] However, to date, other more efficient and precise targets and mechanisms of ursolic acid have not been discovered.
[0005] Clinically, there is currently no drug with obvious effect on patients with oligospermia. Scientific research has shown that ursolic acid has a promoting effect on oligoasthenospermia caused by lipopolysaccharide. The structure of ursolic acid is similar to that of ursolic acid, which also suggests similar functions. Summary of the invention
[0006] The technical problem to be solved by the present invention is to provide an application of ursolic acid in the preparation of a drug for improving spermatogenesis disorder. The drug prepared by ursolic acid has an improving effect on the treatment of oligospermia in male infertility diseases, has the effects of improving spermatogenesis disorder, increasing sperm concentration, promoting fertility, etc., and ursolic acid is a natural product or an artificially synthesized product with low toxicity and small side effects.
[0007] In order to solve the above technical problems, an embodiment of the present invention provides the use of ursolic acid in the preparation of a drug for improving spermatogenesis disorder. The structural formula of the ursolic acid is shown below:
[0008]
[0009] The preparation steps of ursolic acid are as follows: dissolving ursolic acid in dichloromethane, adding dichlorochromic acid pyridinium salt and stirring at room temperature; reacting overnight; after monitoring the reaction is complete by thin layer chromatography, adding water to extract 3 times, drying the organic layer with anhydrous sodium sulfate, concentrating and eluting with petroleum ether-ethyl acetate by column chromatography to obtain ursolic acid.
[0010] The experimental steps of the effect of ursolic acid on oligospermia in mice are as follows:
[0011] Step 1: The experimental animals were randomly divided into three groups: model group, blank group, and ursolic acid administration group;
[0012] Step 2: Prepare a solution of busulfan at a concentration of 6 mg / mL. Except for the blank group, mice in the other groups were given intraperitoneal injection at a dose of 30 mg / kg to form an oligospermia mouse model;
[0013] Step 3: The ursolic acid group was given ursolic acid by intragastric administration at a dose of 50 mg / kg body weight, while the model group and the blank group were given 0.2 mL of solvent by intragastric administration every day;
[0014] Step 4: Extract epididymal semen, use CASA computer-assisted sperm quality analysis system to detect sperm density, sperm motility, and percentage of forward-moving sperm in mice, detect testicular morphology recovery in mice, use Elisa kit to detect ROS, MDA, and SOD1 levels in mouse testis, and use Elisa kit to detect serum gonadal hormone testosterone and luteinizing hormone levels in each group of mice, and follicle-stimulating hormone. Frozen sections of mouse testicular tissue were stained with HE to detect testicular tissue morphology recovery.
[0015] Wherein, in the drug for improving spermatogenesis disorder, the effective dosage range of ursolic acid is 0.01ug / mL-10ug / ml.
[0016] Among them, the drug for improving spermatogenesis disorder is an oral preparation, injection, granule, pill, capsule, powder, sustained release, controlled release preparation, targeted preparation or preparation for other administration routes.
[0017] The beneficial effects of the above technical solution of the present invention are as follows:
[0018] The invention prepares a drug for improving spermatogenesis disorder by using ursolic acid, has an improving effect on treating oligospermia in male infertility diseases, has the effects of improving spermatogenesis disorder, increasing sperm concentration, promoting fertility, etc., and ursolic acid is a natural product or an artificially synthesized product with low toxicity and small side effects. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 This is the acid hydrogen spectrum of the compound ursolic acid;
[0020] Figure 2 This is the carbon spectrum of the compound ursolic acid;
[0021] Figure 3 This is a HE staining comparison of the model group, blank group, and ursolic acid administration group in Example 2. DETAILED DESCRIPTION
[0022] In order to make the technical problems, technical solutions and advantages to be solved by the present invention more clear, a detailed description will be given below with reference to the accompanying drawings and specific embodiments.
[0023] An embodiment of the present invention provides an application of ursolic acid in the preparation of a drug for improving spermatogenesis disorder. In the drug for improving spermatogenesis disorder, the effective dose range of ursolic acid is 0.01ug / mL-10ug / ml, and the drug for improving spermatogenesis disorder can be an oral preparation, injection, granule, pill, capsule, powder, sustained release, controlled release preparation, targeted preparation or preparation for other administration routes.
[0024] Example:
[0025] 1. Preparation of ursolic acid:
[0026] The chemical structure of an ursolic acid crystalline compound is shown in formula (I):
[0027]
[0028] The ursolic acid crystal compound is a white powder, with mp: 283° C. and EI-MS m / Z: 454.34.
[0029] The synthetic route of the compound of formula (I) is as follows:
[0030]
[0031] The preparation method is:
[0032] S1. Dissolve 5 g of ursolic acid in 150 ml of dichloromethane, add 6.18 g (1.5 eq.) of pyridinium dichromate (PDC), stir at room temperature, and react overnight;
[0033] S2. Monitor the reaction by thin layer chromatography. After the reaction is complete, add 150 ml of water to extract three times, dry the organic layer with anhydrous sodium sulfate, concentrate, and elute with petroleum ether-ethyl acetate (5:1) by column chromatography to obtain 4.82 g of ursolic acid with a yield of 96.8%. See the attached hydrogen and carbon spectra. Figure 1 and attached Figure 2 .
[0034] 1H NMR(500MHz,CD3OD-d4)H:5.26(1H,t,J=3.7Hz),2.52-2.59(1H,m),2.37-2.42(1H,m),2.22(1H,dd,J=11.4,1.8Hz),2.01-2.08(1H,m),1.97- 2.01(2H,m),1.89-1.96(2H,m),1.14(3H,s),1.08(3H,s),1.07(3H,d,J =3.3Hz),1.05(3H,s),0.97(3H,s),0.90(3H,s),0.89(3H,d,J=6.5Hz).
[0035] 13 C NMR(100MHz,CD3OD-d4)C:220.52,181.58,139.70,126.73,56.40,54.43,43.38,40.72,40.40,38.08 ,37.82,35.10,33.77,31.77,29.20,27.09,25.30,24.50,24.01,21.92,21.57,20.72,17.68,15.74.
[0036] 2. Experimental results of ursolic acid in improving oligospermia
[0037] The experimental steps are as follows:
[0038] After 30 mature 8-week-old ICR male mice were fed for 3 days, they were randomly divided into 3 groups, namely the model group, the blank group and the ursolic acid administration group, with 10 mice in each group. Busulfan was prepared into a solution with a concentration of 6 mg / mL. Except for the blank group mice, all other groups were intraperitoneally injected with a dose of 30 mg / kg to create an oligospermia mouse model. Two weeks later, the ursolic acid group was treated with ursolic acid by gavage at a dose of 50 mg / kg body weight, while the model group and the blank group were gavaged with 0.2 mL of solvent daily, and each group was gavaged for 28 consecutive days. During the experiment, the general state of the mice (such as hair, activity, body shape, etc.) was observed, and the daily water intake and food intake were measured. After the experiment, all mice were killed, blood was taken from the heart, serum was separated, testicles, gonads and accessory gonads were removed and weighed, and epididymal semen was extracted. The CASA computer-assisted sperm quality analysis system was used to detect the sperm density, sperm motility, and percentage of forward-moving sperm in each group of mice; the recovery of testicular morphology of mice was detected; Elisa kits were used to detect the levels of ROS, MDA, and SOD1 in the testes of mice; Elisa kits were used to detect the levels of serum gonadal hormones testosterone (T), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) in each group of mice. The frozen sections of mouse testicular tissue were stained with HE to detect the recovery of testicular tissue morphology.
[0039] The experimental results showed that the sperm count and sperm motility test results of the blank group were compared with those of the model group, and the differences were statistically significant (P<0.05). Compared with the model group, the sperm count of the ursolic acid-treated group was significantly increased, and the difference was statistically significant (P<0.05).
[0040] HE staining results showed that Figure 3 As shown, compared with the normal group, the testicular tissue morphology of the model group was significantly damaged, the spermatogenesis process was disordered, and the spermatogenic cells were lost; compared with the model group, the testicular tissue morphology, spermatogenesis process and spermatogenic cells of the mice in the ursolic acid administration group were significantly restored.
[0041] The above experiments show that ursolic acid has a significant therapeutic effect on oligospermia model mice. After 4 weeks of continuous administration, the sperm count of oligospermia mice has increased significantly. Ursolic acid has a promoting effect on the sperm concentration of mice at different concentrations.
[0042] Therefore, ursolic acid can be used to prepare drugs for improving spermatogenesis disorders, which has an improving effect on the treatment of oligospermia in male infertility diseases, and has the effects of improving spermatogenesis disorders, increasing sperm concentration, and promoting fertility. Moreover, ursolic acid is a natural product or an artificially synthesized product with low toxicity and small side effects.
[0043] The above is a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. Application of ursolic acid in the preparation of drugs for improving spermatogenesis disorders; The structural formula of ursolic acid is shown below: 。 2. The use of ursolic acid according to claim 1 in the preparation of a drug for improving spermatogenesis disorders, It is characterized in that The preparation steps of ursolic acid are as follows: dissolving ursolic acid in dichloromethane, adding dichlorochromic acid pyridinium salt and stirring at room temperature; reacting overnight; after monitoring the reaction completion by thin layer chromatography, adding water to extract 3 times, drying the organic layer with anhydrous sodium sulfate, concentrating and eluting with petroleum ether-ethyl acetate by column chromatography to obtain ursolic acid.
3. The use of ursolic acid according to claim 1 in the preparation of a drug for improving spermatogenesis disorder, It is characterized in that The experimental steps of the effect of ursolic acid on oligospermia in mice are as follows: Step 1: The experimental animals were randomly divided into three groups: model group, blank group, and ursolic acid administration group; Step 2: Prepare a solution of busulfan at a concentration of 6 mg / mL. Except for the blank group, mice in the other groups were given intraperitoneal injection at a dose of 30 mg / kg to form an oligospermia mouse model; Step 3: The ursolic acid group was given ursolic acid by intragastric administration at a dose of 50 mg / kg body weight, while the model group and the blank group were given 0.2 mL of solvent by intragastric administration every day; Step 4: Extract epididymal semen, use CASA computer-assisted sperm quality analysis system to detect sperm density, sperm motility, and percentage of forward-moving sperm in mice, detect testicular morphology recovery in mice, use Elisa kit to detect ROS, MDA, and SOD1 levels in mouse testis, and use Elisa kit to detect serum gonadal hormone testosterone and luteinizing hormone levels in each group of mice, and follicle-stimulating hormone. Frozen sections of mouse testicular tissue were stained with HE to detect testicular tissue morphology recovery.
4. The use of ursolic acid according to claim 1 in the preparation of a drug for improving spermatogenesis disorder, It is characterized in that In the drug for improving spermatogenesis disorder, the effective dosage range of ursolic acid is 0.01ug / mL-10ug / ml.
5. Use of ursolic acid according to claim 1 in preparing a drug for improving spermatogenesis disorder, It is characterized in that The drug for improving spermatogenesis disorder is an oral preparation, an injection, a sustained-release preparation, a controlled-release preparation, and a targeted preparation.
6. Use of ursolic acid according to claim 5 in the preparation of a drug for improving spermatogenesis disorders, It is characterized in that The oral preparations include granules, pills, capsules and powders.
